Abeona Therapeutics (NASDAQ:ABEO) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com lowered Abeona Therapeutics from a hold rating to a sell rating in a research note on Tuesday.

Abeona Therapeutics Trading Up 0.6 %

NASDAQ ABEO opened at $3.19 on Tuesday. Abeona Therapeutics has a 1-year low of $2.83 and a 1-year high of $9.01. The stock has a 50-day moving average of $7.37 and a 200-day moving average of $5.63. The firm has a market cap of $87.25 million, a PE ratio of -1.22 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). As a group, equities research analysts forecast that Abeona Therapeutics will post -1.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. raised its position in Abeona Therapeutics by 84.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after purchasing an additional 1,488,834 shares during the last quarter. AIGH Capital Management LLC raised its position in Abeona Therapeutics by 77.7% during the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock valued at $4,779,000 after purchasing an additional 496,278 shares during the last quarter. Citigroup Inc. raised its position in Abeona Therapeutics by 125.0% during the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after purchasing an additional 250,000 shares during the last quarter. Barclays PLC raised its position in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the last quarter. Finally, Worth Venture Partners LLC raised its position in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.